Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial | Synapse
March 3, 2026
Sulforaphane Adjunct to Methylphenidate for Attention-deficit/Hyperactivity Disorder: A Randomized, Double-blind, Placebo-controlled Trial
Key Points
Inattention and hyperactivity improved with sulforaphane treatment, indicating potential benefits for ADHD symptoms.
Children receiving sulforaphane along with methylphenidate showed enhanced symptom management.
Randomized double-blind placebo-controlled trial assessed sulforaphane as an adjunct to standard treatment.
Findings highlight the need for further exploration of sulforaphane in managing ADHD.
Abstract
Sulforaphane adjunct to methylphenidate was beneficial for inattention, hyperactivity-impulsivity, and total symptoms of children with ADHD safely and tolerably.